Psych Disorders May Reduce Response to CGRPs for Migraine

Patients with migraine are less likely to respond to the new CGRP monoclonal antibody preventive treatments, if they have certain psychiatric disorders, new research shows.

Related Keywords

Sweden ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Rome ,Lazio ,Italy ,Italian ,Fabrizio Vernieri ,Lars Edvinsson ,Sara Bottiroli ,Lund University Hospital ,University Of Pavia ,Campus Bio Medico University Hospital Foundation ,European Headache Congress ,Structured Clinical Interview ,Psychological Differences ,Migraine Headache ,Anxiety ,Mental Illness ,Mental Disorder ,Sychiatric Disorder ,Sychiatric Illness ,Monoclonal Antibody ,Etuximab ,Ituximab ,Personality Disorder ,Stress ,Anxiety Disorder ,Pain Management ,Hospitals ,Biologic Therapy ,Iologics ,Allodynia ,Body Mass Index ,Mi ,Brain ,Central Sensitization Sensitisation ,Children ,Child ,Childhood ,Ediatrics ,Kids ,